Clinical trials: Relapsed Cancer
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Acute T Cell Leukemia
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute…
- Trial name
- NCT03613428
- Testing
- Ruxolitinib, Vincristine, Prednisone
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Neuroblastoma, Relapsed Neuroblastoma
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
Subjects with relapsed or refractory neuroblastoma and osteosarcoma will receive ex-vivo expanded and activated natural killer (NK) cells from a haploidentical donor in conjunction with the immunocytokine, hu14.18-IL2.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Recurrent Neuroblastoma, Osteosarcoma
- Trial name
- NCT03209869
- Testing
- Ex vivo Expanded and Activated Haploidentical Donor NK Cells, Hu14.18-IL2
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Medulloblastoma, Central Nervous System Embryonal Tumor
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young…
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma
- Trial name
- NCT07087002
- Testing
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT03671460
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Mycure Medical Technology Co., Ltd
Neuroblastoma
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy…
- Trial name
- NCT03107988
- Testing
- Lorlatinib, Cyclophosphamide, Topotecan
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Eye Cancer, Retinoblastoma
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
While 95% of patients with retinoblastoma can be cured nowadays, treatment of relapse remains challenging, ending often in enucleation and/or radiotherapy.
- Trial name
- EuRbG2018 (NCT04455139)
- Testing
- Topotecan, Melphalan
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Prof. Beck Popovic Maja
Central Nervous System Neoplasm, Solid Neoplasm
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system…
- Trial name
- NCT01538095
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 22 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies, Regulatory T Cell Depletion
Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells
The investigators have previously shown the absence of toxicity of Treg-depleted-DLI and the possibility to triggering alloreactivity (GVHD/GVT) in relapsing patients dealing with hematological malignancies who had never shown…
- Conditions
- Hematological Malignancies, Regulatory T Cell Depletion, Relapse
- Trial name
- DLI-Boost (NCT03236129)
- Testing
- T-reg depleted DLI, Standard DLI
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pediatric Cancers, Solid Tumor Pediatric
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
- Trial name
- CMD03 (NCT06612645)
- Testing
- B7H3-IL7Ra CAR-T cells
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Chulalongkorn University
Chronic Myeloproliferative Disorders, Leukemia
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00066417
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Solid Tumors, Children
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
The aim of this clinical study is to determine the efficacy and safety of the liposomal mitoxantrone combination regimen in treating relapsed and refractory solid tumors among children, adolescents, and young adults.
- Conditions
- Solid Tumors, Children, Adolescents
- Trial name
- NCT06761417
- Testing
- Mitoxantrone liposome, Capecitabine, Anlotinib
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies.
- Trial name
- KPT-IST-391 (NCT06225310)
- Testing
- Selinexor, Ruxolitinib, Methylprednisolone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oncotherapeutics
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER I (NCT00305448)
- Testing
- Fulvestrant
- Where
- 35 sites in Japan
- Volunteers
- 143 people
- Sponsor
- AstraZeneca
Leukemia, Lymphoma
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
This is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of Auto CAR-T cell injection in the treatment of recurrent or refractory Hematopoietic and Lymphoid Tissue Tumors in Children
- Trial name
- NCT04610125
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again…
- Trial name
- NCT05932290
- Testing
- Elranatamab, Standard of care
- Where
- United States
- Volunteers
- 514 people
- Sponsor
- Pfizer
Lymphoma
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00078949
- Testing
- rituximab, cisplatin, cytarabine
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 849 people
- Sponsor
- NCIC Clinical Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.